Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings
Clinical and Translational Imaging · 14.04.2026 · 14 (4) · 353-366
DOI: 10.1007/s40336-026-00766-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Imaging, online erschienen am 14.04.2026. Verfasst von Matteo Bauckneht und 39 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Genova.
Abstract (Originalsprache)
Background
Prostate-specific membrane antigen (PSMA) PET/CT has transformed prostate cancer (PCa) management by improving lesion detection and guiding treatment decisions across disease stages. Following the first paper of the Italian PSMA Survey focused on technical aspects and primary staging, this second analysis explores its clinical use in PSA persistence after radical prostatectomy, biochemical recurrence (BCR), hormone-sensitive metastatic (mHSPC), and castration-resistant metastatic (mCRPC) settings.
Methods
A national cross-sectional survey was conducted jointly by five Italian scientific societies involving nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists (AIMN, AIOM, AIRO, SIU, SIUrO) and the Meet-URO cooperative group. Dedicated sections addressed the adoption, timing, and perceived clinical impact of PSMA PET/CT in PSA persistence after radical prostatectomy, BCR, mHSPC, and mCRPC. Responses were analysed descriptively and stratified by medical competences (clinicians versus nuclear medicine physicians).
Results
PSMA PET/CT emerged as the preferred imaging modality in all clinical scenarios. In PSA persistence and BCR, 87–95% of respondents selected PSMA PET as first-line imaging, most often performed at PSA levels of 0.2–0.5 ng/mL. When negative, more than two-thirds recommended repeating PSMA PET/CT after PSA further rise. In mHSPC, over 80% of clinicians applied the CHAARTED criteria directly to PSMA PET findings, while PSMA PET/CT was also widely used for restaging and therapy monitoring. In mCRPC, PSMA PET/CT was routinely used for baseline and follow-up imaging. Most clinicians considered the low-dose CT component sufficient for radioligand therapy (RLT) eligibility, while [ 18 F]Fluorodeoxyglucose (FDG) PET was reserved for selected high-risk or discordant cases.
Conclusion
PSMA PET/CT has become the central imaging modality in the management of advanced PCa in Italy. Its adoption has progressed faster than supporting evidence, underscoring the need for prospective validation, implementation of harmonised interpretation criteria, and unified national recommendations.
Förderung
- Università degli Studi di Genova
Zitieren
APA
Bauckneht, M., Evangelista, L., Sofia, L., Maccauro, M., Filice, A., Rimini, M. L. D., Caffo, O., Messina, C., Maruzzo, M., Pinterpe, G., Krengli, M., Mari, A., Schiavina, R., Bracarda, S., D’Angelillo, R. M., Lapini, A., Zucali, P. A., Fornarini, G., Abate, R., …, & Basso, U. (2026). Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings. Clinical and Translational Imaging, 14(4), 353-366. https://doi.org/10.1007/s40336-026-00766-8
Vancouver
Bauckneht M, Evangelista L, Sofia L, Maccauro M, Filice A, Rimini MLD, et al. Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings. Clinical and Translational Imaging. 2026;14(4):353-366. doi:10.1007/s40336-026-00766-8
BibTeX
@article{Bauckneht2026,
author = {Bauckneht, Matteo and Evangelista, Laura and Sofia, Luca and Maccauro, Marco and Filice, Angelina and Rimini, Maria Luisa De and Caffo, Orazio and Messina, Carlo and Maruzzo, Marco and Pinterpe, Giada and Krengli, Marco and Mari, Andrea and Schiavina, Riccardo and Bracarda, Sergio and D’Angelillo, Rolando Maria and Lapini, Alberto and Zucali, Paolo Andrea and Fornarini, Giuseppe and Abate, Raffaela and Albano, Domenico and Alberti, Andrea and Allis, Simona and Alongi, Filippo and Alongi, Pierpaolo and Ambrosini, Francesca and Antonelli, Luca and Antonica, Filippo and Arena, Gabriella and Aricò, Demetrio and Atzori, Francesco and Badalamenti, Marco and Baiocco, Cinzia and Baldazzi, Valentina and Baldoncini, Alfonso and Bambaci, Michelangelo and Bardino, Gian Franco and Bardoscia, Lilia and Barsacchi, Lucia and Barzaghi, Domenico and Basso, Umberto},
title = {Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings},
journal = {Clinical and Translational Imaging},
year = {2026},
volume = {14},
number = {4},
pages = {353--366},
doi = {10.1007/s40336-026-00766-8}
}
EUVIMED